N/A N=1,150 Randomized Endo-Vein Graft Prospective
Coronary Artery Bypass Grafting
Primary: Incidence of First MACE During Active Follow-up Period. — 80; 89 Participants — p=0.47
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=733 Radial Artery Versus Saphenous Vein Grafts in Coronary Artery Bypass Surgery
Cardiovascular Disease · Coronary Artery Disease
Primary: To Compare 1-year Angiographic Patency of Radial Artery Grafts Versus Saphenous Vein Grafts in Patients Undergoing Elective Coronary Artery Bypass Graft (CABG) Surgery…
N/A N=72 Preventing Seroma Formation After Stripping Saphenous Vein in Coronary Bypass
Coronary Bypass Graft Stenosis of Autologous Vein
Primary: Early Complications of Vascular Zone — 1; 4; 15; 5 participants — p=0.05
Phase 3 N=173 Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)
Saphenous Vein Graft Disease
Primary: Saphenous Vein Graft Occlusion (Percentage of Vein Grafts Occluded) Based on CT Coronary Angiography at 1 Year — 14; 16 Vein grafts
Phase 4 N=597 Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty
Saphenous Vein Graft Atherosclerosis
Primary: Number of Participants With Target Vessel Failure (TVF), Defined as the Composite of Cardiac Death — 16; 17 Participants
N/A N=224 A Prospective Randomized Study for Comparison of Y-Composite Grafts
Coronary Artery Disease
Primary: 1 Year Graft Patency Rates — 97.1; 97.1 percentage of distal anastomoses
N/A N=124 GORE® VIABAHN® Endoprosthesis Post-Marketing Surveillance Study
Vascular Stent-Graft Stenosis
Primary: Number of Subjects With Loss of Primary Patency of Target Lesion — 81 Participants
Phase 4 N=250 Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis
Saphenous Vein Graft Disease
Primary: Saphenous Vein Graft Occlusion — 17.4; 13.2 percentage of veins occluded
Phase 4 N=91 Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery
Arteriosclerosis of Coronary Artery Bypass Graft
Primary: Technical Success (Graft Patency) in a MICS Approach — 100 percentage of grafts
Phase 3 N=84 Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis
Coronary Artery Bypass
Primary: Prevalence of Intragraft Thrombus at 12-month Follow-up Optical Coherence Tomography Imaging — 14; 14 Participants — p=0.78
N/A N=19 Endothelial Function in Lower Extremity Bypass Grafts
Peripheral Arterial Disease
Primary: Change From Baseline in Saphenous Vein Bypass Graft Vasodilation — 5.28 vein bypass graft size increase (%)
Phase 3 N=293 GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis
Renal Failure · Hemodialysis
Primary: Target Lesion Primary Patency at 6 Months — 52.9; 35.5 Percentage of Subjects
N/A N=110 Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft in AV Graft Patients (AVeVA)
Stenosis · Restenosis
Primary: Number of Participants With Freedom From AV Access Circuit Localized or Systemic Serious Adverse Events — 106 Participants — p=0.0021
Phase 3 N=142 Radial Artery Versus Saphenous Vein Patency (RSVP) Study
Coronary Arteriosclerosis
Primary: Patency Rates — 38; 58; 6; 1 Participants
N/A N=158 Clinical Evaluation of a Vascular Venous Anastomotic Connector [InterGraft VIG-only Study]
End Stage Renal Disease
Primary: Cumulative Patency at 6 Months — 146 Participants — p=<0.001
Phase 4 N=148 GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study
Peripheral Vascular Diseases
Primary: Efficacy: Primary Patency at Three Years — 24.2; 25.9 percentage of subjects
N/A N=280 Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft
Stenosis · Restenosis
Primary: Effectiveness Endpoint: Number of Participants With Target Lesion Primary Patency (TLPP) — 105; 55 Participants — p=<0.001
N/A N=116 Comparison of Bidirectional Palpation Test and Transit Time Flow Measurement for LIMA-LAD Graft Patency
Coronary Arterial Disease (CAD) · Coronary Artery Bypass · LIMA
Primary: Reliability of Bidirectional Palpation Test (BPT) in Evaluating LIMA-LAD Graft Patency — 2; 2; 2; 2 Participants — p=<0.001
Phase 3 N=2,203 Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass
Ischemic Heart Disease
Primary: Short-term End Point — 61; 77 participants
N/A N=275 FLUENCY® PLUS Endovascular Stent Graft for In-stent Restenosis
Restenosis
Primary: Percentage of Participants With Access Circuit Primary Patency (ACPP) That is Superior for FLUENCY® PLUS Endovascular Stent Graft (Following Percutaneous Transluminal…
N/A N=301 Comparing the Effectiveness of a Mitral Valve Repair Procedure in Combination With Coronary Artery Bypass Grafting (CABG) Versus CABG Alone in People With Moderate Ischemic Mitral Regurgitation
Mitral Valve Insufficiency · Coronary Artery Disease
Primary: Degree of Left Ventricular Remodeling, as Assessed by Left Ventricular End Systolic Volume Index (LVESVI) — 49.6; 46.1 ml per square meter — p=0.61
N/A N=200 ABRE Clinical Study of the Abre Venous Self-expanding Stent System
Iliofemoral Venous Obstruction
Primary: Primary Patency — 162 Participants — p=<0.0001
N/A N=5 Safety and Performance of the COR-VG-001 Conduit in Pediatric Patients for Extracardiac Total Cavopulmonary Connection
Heart Defects, Congenital
Primary: The Number of Graft Related Post-operative Complications That Require a Repeat Surgery or a Non Surgical Treatment Within 12-month Post Implantation. — 0 Participants
N/A N=207 Study Comparing Synthetic Vascular Grafts in Patients With Peripheral Artery Disease (PAD) Who Require Artery Bypass.
Peripheral Arterial Occlusive Disease
Primary: Number of Participants With Primary Patency — 70; 89 Participants — p=<.0001
N/A N=134 A Study of the Gore VIABAHN BX for Treatment of Occlusive Disease in the Iliac Arteries.
Peripheral Arterial Disease
Primary: Composite of Major Adverse Events (MAEs) — 2.3 percentage of subjects experiencing MAE — p=<0.001
Phase 4 N=30 Transepicardial With Transseptal Autologous CD 133+ Bone Marrow Cell Implantation in Patient Following CABG Surgery
Coronary Artery Disease
Primary: Myocardial Defect Perfusion — 15.76; 15.38; 2.08; 3.85 Percentage of Myocardial Perfusion
N/A N=93 AngioSculpt® Coronary Bifurcation Study
Coronary Artery Disease · Myocardial Ischemia
Primary: Procedural Success — 91.4 percentage of participants
Phase 4 N=500 Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery
Coronary Artery Bypass · Antiplatelet Agents
Primary: The Patency of Saphenous Vein Grafts — 76.5; 88.7; 82.8 percentage of patent SV grafts
N/A N=117 Autologous Bone Marrow Mononuclear Cells in the Combined Treatment of Coronary Heart Disease
Ischemic Heart Disease · Bone Marrow Cells · Coronary Artery Bypass Grafting (CABG)
Primary: Assessment of the Initial Risk of Surgery (EuroScore II). — 1.3; 1.07; 1.02 percent — p=0.24
N/A N=78 DETOUR I Clinical Study for Percutaneous Femoropopliteal Bypass
Peripheral Arterial Disease
Primary: Number of Lesions With Primary Patency — 72 Lesions